Market Data
Market Cap₹48,712.48 Cr.
52W High₹2,039.3
Current Price₹1,920.05
52W Low₹1,252.95
Down from 52W High5.8 %
Face Value₹1
Performance
ROCE21.48 %
ROE16.24 %
EPS (TTM)₹15.84
EPS Prev Qtr₹13.31
EPS Last Year₹11.14
EBITDA Qtr₹558.7 Cr.
Book Value₹318
Financial Health
Debt/Equity0.09
Debt/Profit0.51
Total Assets₹12,370.19 Cr.
Dividend Yield0.31 %
Promoter Holding44.72 %
Earning Power14.57 %
Valuation
Stock P/E36.13
Industry P/E33.81
Price to Book6.04
Price to Sales4.81
Graham Number₹616.57
Key Metrics
__derived
1
Face Value
₹1
About Ipca Laboratories Ltd
Healthcare · Pharmaceuticals
Ipca Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹1. Market cap ₹48,712.48 Cr.
Price Chart
Strengths & Weaknesses
Strengths
- The company has a strong ROCE of 21.48%, indicating efficient use of capital.
- ROE stands at 17.11%, reflecting good return generation for shareholders.
- The company maintains a low debt-to-equity ratio of 0.09, suggesting a conservative capital structure.
- Promoter holding is at a healthy 44.72%, indicating strong management control and alignment of interests.
Weaknesses
- The P/E ratio of 36.85 suggests the stock may be overvalued relative to earnings.
- The P/B ratio of 6.16 indicates the market values the company at a premium over its book value.
- The dividend yield is low at 0.31%, offering limited income to investors.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 20.8% YoY, Profit grew 80.4% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 2,308.85 | 2,556.5 | 2,392.5 | 2,388.48 | 2,788.1 |
| ↳ QoQ Growth | - | +10.7% | -6.4% | -0.2% | +16.7% |
| Expenses | 1,992.49 | 2,114.91 | 1,966.74 | 2,011.75 | 2,229.4 |
| Operating Profit | 316.36 | 441.59 | 425.76 | 376.73 | 558.7 |
| OPM % | 13.7% | 17.27% | 17.8% | 15.77% | 20.04% |
| Other Income | 32.66 | 27.86 | 20.19 | 93.74 | 25.26 |
| Interest | 18.51 | 19.61 | 17.62 | 20.2 | 11.88 |
| Depreciation | 100.06 | 103.33 | 107.59 | 107.14 | 110.81 |
| EBITDA | 416.42 | 544.92 | 533.35 | 483.87 | 669.51 |
| EBITDA Margin % | 18.04% | 21.32% | 22.29% | 20.26% | 24.01% |
| Profit Before Tax | 330.51 | 391.58 | 445.98 | 404.45 | 572.08 |
| Tax % | 29.07% | 27.6% | 18.37% | 23.5% | 26.09% |
| Net Profit | 234.42 | 283.5 | 364.05 | 309.4 | 422.81 |
| ↳ QoQ Growth | - | +20.9% | +28.4% | -15.0% | +36.7% |
| EPS | 9.19 | 11.14 | 12.86 | 13.31 | 15.84 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 9646.33 | 10125.58 |
| Expenses | 8085.89 | 8322.8 |
| Operating Profit | 1560.44 | 1802.78 |
| OPM % | 16.18% | 17.8% |
| Other Income | 174.45 | 167.05 |
| Interest | 75.94 | 69.31 |
| Depreciation | 418.12 | 428.87 |
| Profit Before Tax | 1572.52 | 1814.09 |
| Tax % | 24.24% | 23.94% |
| Net Profit | 1191.37 | 1379.76 |
| EPS | 46.5 | 53.15 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
45.46%
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
17.11%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 25.37 | 25.37 |
| Reserves | 6923.08 | 8038.44 |
| Borrowings | 1362.74 | 703.94 |
| Other Liabilities | 3449.36 | 3602.44 |
| Total Liabilities | 11760.55 | 12370.19 |
| Fixed Assets | 4069.17 | 4638.17 |
| CWIP | 616.17 | 761.59 |
| Investments | 979.71 | 843.56 |
| Other Assets | 6095.5 | 6126.87 |
| Total Assets | 11760.55 | 12370.19 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | 1141.97 |
| Cash from Investing Activity | -246.77 |
| Cash from Financing Activity | -753.53 |
| Net Cash Flow | 141.67 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 441.43 |
| ROCE % | 13.38% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 44.72% | 44.72% | 44.72% | 44.72% |
| FIIs % | 10.43% | 10.63% | 10.63% | 10.73% |
| DIIs % | 36.77% | 37.32% | 37.45% | 37.37% |
| Public % | 6.55% | 5.88% | 5.79% | 5.76% |
| No. of Shareholders | 82,870 | 77,673 | 82,184 | 82,060 |
Major Shareholders (>1%)
- Kaygee Investments Private LimitedPromoter and Promoter Group25.49%
- Hdfc Mutual FundPublic Shareholding9.54%
- Kaygee Laboratories Private LimitedPromoter and Promoter Group6.61%
- Kotak Mahindra Mutual FundPublic Shareholding6.36%
As of 2026-06-30View all shareholders →